Joel Sunshine
Overview
Explore the profile of Joel Sunshine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1071
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DAmiano A, Kollings J, Madan V, Sunshine J
J Am Acad Dermatol
. 2025 Feb;
PMID: 39986395
No abstract available.
2.
Pierog O, Rozati S, Sunshine J
Am J Dermatopathol
. 2023 Nov;
46(1):40-42.
PMID: 37982504
No abstract available.
3.
Deutsch J, Cimino-Mathews A, Thompson E, Provencio M, Forde P, Spicer J, et al.
Nat Med
. 2023 Oct;
30(1):218-228.
PMID: 37903504
Neoadjuvant immunotherapy plus chemotherapy improves event-free survival (EFS) and pathologic complete response (0% residual viable tumor (RVT) in primary tumor (PT) and lymph nodes (LNs)), and is approved for treatment...
4.
Griffith P, Jedrych J, Sunshine J, Laheru D, Yarchoan M
Cureus
. 2022 Feb;
14(1):e21478.
PMID: 35223258
Specific fibroblast growth factor receptor (FGFR) inhibitors have been developed to treat malignancies harboring fusions or rearrangements in FGFR2 or FGFR3. Here, we report a case of calciphylaxis cutis in...
5.
Borner K, Teichmann S, Quardokus E, Gee J, Browne K, Osumi-Sutherland D, et al.
Nat Cell Biol
. 2021 Nov;
23(11):1117-1128.
PMID: 34750582
The Human Reference Atlas (HRA) aims to map all of the cells of the human body to advance biomedical research and clinical practice. This Perspective presents collaborative work by members...
6.
Danilova L, Wang H, Sunshine J, Kaunitz G, Cottrell T, Xu H, et al.
Proc Natl Acad Sci U S A
. 2016 Nov;
113(48):E7769-E7777.
PMID: 27837027
Programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockade has led to remarkable and durable objective responses in a number of different tumor types. A better understanding of factors...
7.
Sunshine J, Taube J
Curr Opin Pharmacol
. 2015 Jun;
23:32-8.
PMID: 26047524
Tumors may adopt normal physiologic checkpoints for immunomodulation leading to an imbalance between tumor growth and host surveillance. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions,...
8.
Sunshine J, Green J, Mahon K, Yang F, Eltoukhy A, Nguyen D, et al.
Adv Mater
. 2014 Aug;
21(48):4947-4951.
PMID: 25165411
End-modified polymers are promising for the nonviral delivery of genes to cancer cells, immune cells, and human stem cells and point to polymer end-groups as regulators for cell-type specificity. A...
9.
Sunshine J, Bhise N, Green J
Annu Int Conf IEEE Eng Med Biol Soc
. 2009 Dec;
2009:2412-5.
PMID: 19964958
Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure led...
10.
Lee J, Green J, Love K, Sunshine J, Langer R, Anderson D
Nano Lett
. 2009 May;
9(6):2402-6.
PMID: 19422265
The safe and effective delivery of RNA therapeutics remains the major barrier to their broad clinical application. Here we develop a new nanoparticulate delivery system based on inorganic particles and...